Retatrutide (development code LY3437943 ) is a single synthetic peptide developed by Eli Lilly that acts as a triple agonist at three receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor
A meta-analysis covering over 28,000 patients found that while the overall rate of GI adverse events was similar (approximately 5253% of patients in both groups), serious adverse events occurred somewhat more frequently with higher tirzepatide doses (5.37% at 1015 mg) compared to semaglutide (2.8%)
This is due to the risk of adverse effects, as well as the risk of abuse and misuse, as people often use Viagra for recreational purposes
Secretin is composed of 27 amino acids in a linear structure and has a similar sequence to glucagon, VIP (Vasoactive Intestinal Peptide), and GIP (Gastric Inhibitory Peptide)
Patients should ask what form is being used (base versus salt forms for semaglutide), and understand FDA warnings about compounded GLP-1 products
